PIK3CA activating mutations, clustered in exons 9 (helical domain) and 20 (kinase domain) have been reported in 18–40% BC, occasionally associated with HER2 phenotype (Stemke-Hale et al, 2008) and tumour recurrence (Razis et al, 2011). Here, ERBB2 is linked to breast cancer.